<p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）在週一發佈的研究報告中被 StockNews.com 的股票分析師從 “買入” 評級下調至 “持有” 評級。</p>
<p>其他研究分析師最近也對該公司發佈了報告。Raymond James 在 12 月 19 日的研究報告中將 Prestige Consumer Healthcare 的評級上調至 “適度買入”。DA Davidson 在 2 月 7 日的研究報告中將 Prestige Consumer Healthcare 的目標價格從 95.00 美元提高至 104.00 美元，並給予該股票 “買入” 評級。Oppenheimer 在 2 月 13 日的研究報告中將 Prestige Consumer Healthcare 的目標價格從 87.00 美元提高至 93.00 美元，並給予該股票 “跑贏大盤” 評級。Canaccord Genuity Group 在 2 月 7 日的報告中將 Prestige Consumer Healthcare 的目標價格從 93.00 美元提高至 100.00 美元，並給予該公司 “買入” 評級。最後，Sidoti 在 12 月 9 日的報告中將 Prestige Consumer Healthcare 的評級從 “買入” 下調至 “中性”，並設定了 90.00 美元的目標價格。三位分析師對該股票給予了持有評級，三位分析師則給予了買入評級。根據 MarketBeat 的數據，Prestige Consumer Healthcare 目前的共識評級為 “適度買入”，共識目標價格為 92.60 美元。</p>
<p><strong>獲取我們最新的 PBH 股票分析</strong></p>
<h2>Prestige Consumer Healthcare 價格表現</h2>
<p>週一，PBH 股票在交易中下跌 2.38 美元，報 86.64 美元。該公司的交易量為 535,883 股，而其平均交易量為 333,129 股。該公司的 50 日移動平均價格為 80.99 美元，200 日移動平均價格為 78.00 美元。該公司的流動比率為 3.68，速動比率為 2.20，債務與股本比率為 0.56。該公司的市值為 42.9 億美元，市盈率為 20.29，市盈增長比率為 2.69，貝塔值為 0.46。Prestige Consumer Healthcare 的 52 周低點為 62.35 美元，52 周高點為 90.04 美元。</p>
<p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）最近在 2 月 6 日發佈了季度財報。該公司報告季度每股收益為 1.22 美元，超出分析師共識預期的 1.18 美元，超出幅度為 0.04 美元。Prestige Consumer Healthcare 的股本回報率為 12.36%，淨利潤率為 19.13%。股票研究分析師預計，Prestige Consumer Healthcare 在當前財政年度將發佈 4.5 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>幾家對沖基金最近對該公司的持倉進行了調整。Kestra Investment Management LLC 在第四季度購買了 Prestige Consumer Healthcare 的新股份，價值約 27,000 美元。CIBC 私人財富集團在第四季度將其在 Prestige Consumer Healthcare 的股份增加了 48.9%。CIBC 私人財富集團目前擁有該公司 463 股股票，價值 34,000 美元，此前在上個季度又購買了 152 股。Headlands Technologies LLC 在第四季度購買了 Prestige Consumer Healthcare 的新職位，價值約 40,000 美元。亨廷頓國家銀行在第三季度將其在 Prestige Consumer Healthcare 的股份增加了 39.9%。亨廷頓國家銀行目前擁有 635 股該公司的股票，價值 46,000 美元，此前在上個季度又購買了 181 股。最後，McIlrath &amp; Eck LLC 在第四季度將其在 Prestige Consumer Healthcare 的持股增加了 19.1%。McIlrath &amp; Eck LLC 目前擁有該公司 959 股股票，價值 75,000 美元，此前在此期間又收購了 154 股。99.95% 的股票由機構投資者持有。</p>
<h2>關於 Prestige Consumer Healthcare</h2>
<p>（獲取免費報告）</p>
<p>Prestige Consumer Healthcare Inc 及其子公司在美國和國際上開發、製造、營銷、分銷和銷售非處方（OTC）健康和個人護理產品。該公司分為兩個部門，北美 OTC 醫療保健和國際 OTC 醫療保健。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Prestige Consumer Healthcare</li>
<li>如何從成長投資中獲利</li>
<li>當通貨膨脹上升時，如何保護您的投資組合</li>
<li>精通紀律：克服交易中的情緒挑戰</li>
<li>3 只在 2025 年逆勢而上並蓬勃發展的科技股</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>儘管面臨挑戰，Novo Nordisk 計劃擊敗 GLP-1 競爭對手</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>您現在應該投資 1,000 美元在 Prestige Consumer Healthcare 嗎？</h2>
<p>在您考慮 Prestige Consumer Healthcare 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Prestige Consumer Healthcare 並不在名單上。</p>
<p>雖然 Prestige Consumer Healthcare 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票的詳情</p>

普雷斯蒂奇

<p>StockNews.com 已將 Prestige Consumer Healthcare（紐約證券交易所代碼：PBH）評級從 “買入” 下調至 “持有”。其他分析師的看法不一，Raymond James 將其評級上調至 “適度買入”，而 DA Davidson 則將目標價提高至 104 美元。該股票交易價格下跌至 86.64 美元，市值為 42.9 億美元，市盈率為 20.29。機構投資者持有該股票的 99.95%。Prestige Consumer Healthcare 在北美和國際市場開發和銷售非處方健康產品</p>

<p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) was downgraded by stock analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Monday.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）在週一發佈的研究報告中被 StockNews.com 的股票分析師從 “買入” 評級下調至 “持有” 評級。</p>
</div><p>Other research analysts have also recently issued reports about the company. Raymond James raised Prestige Consumer Healthcare to a &#34;moderate buy&#34; rating in a research report on Thursday, December 19th. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, February 13th. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 7th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $92.60.</p>
<div class="lb-trans"><p>其他研究分析師最近也對該公司發佈了報告。Raymond James 在 12 月 19 日的研究報告中將 Prestige Consumer Healthcare 的評級上調至 “適度買入”。DA Davidson 在 2 月 7 日的研究報告中將 Prestige Consumer Healthcare 的目標價格從 95.00 美元提高至 104.00 美元，並給予該股票 “買入” 評級。Oppenheimer 在 2 月 13 日的研究報告中將 Prestige Consumer Healthcare 的目標價格從 87.00 美元提高至 93.00 美元，並給予該股票 “跑贏大盤” 評級。Canaccord Genuity Group 在 2 月 7 日的報告中將 Prestige Consumer Healthcare 的目標價格從 93.00 美元提高至 100.00 美元，並給予該公司 “買入” 評級。最後，Sidoti 在 12 月 9 日的報告中將 Prestige Consumer Healthcare 的評級從 “買入” 下調至 “中性”，並設定了 90.00 美元的目標價格。三位分析師對該股票給予了持有評級，三位分析師則給予了買入評級。根據 MarketBeat 的數據，Prestige Consumer Healthcare 目前的共識評級為 “適度買入”，共識目標價格為 92.60 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PBH</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 PBH 股票分析</strong></p>
</div><h2>Prestige Consumer Healthcare Price Performance</h2>
<div class="lb-trans"><h2>Prestige Consumer Healthcare 價格表現</h2>
</div><p>PBH stock traded down $2.38 during trading on Monday, hitting $86.64. The company had a trading volume of 535,883 shares, compared to its average volume of 333,129. The company has a fifty day moving average price of $80.99 and a two-hundred day moving average price of $78.00. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.29 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $90.04.</p>
<div class="lb-trans"><p>週一，PBH 股票在交易中下跌 2.38 美元，報 86.64 美元。該公司的交易量為 535,883 股，而其平均交易量為 333,129 股。該公司的 50 日移動平均價格為 80.99 美元，200 日移動平均價格為 78.00 美元。該公司的流動比率為 3.68，速動比率為 2.20，債務與股本比率為 0.56。該公司的市值為 42.9 億美元，市盈率為 20.29，市盈增長比率為 2.69，貝塔值為 0.46。Prestige Consumer Healthcare 的 52 周低點為 62.35 美元，52 周高點為 90.04 美元。</p>
</div><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities research analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare（紐約證券交易所代碼：PBH - 獲取免費報告）最近在 2 月 6 日發佈了季度財報。該公司報告季度每股收益為 1.22 美元，超出分析師共識預期的 1.18 美元，超出幅度為 0.04 美元。Prestige Consumer Healthcare 的股本回報率為 12.36%，淨利潤率為 19.13%。股票研究分析師預計，Prestige Consumer Healthcare 在當前財政年度將發佈 4.5 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several hedge funds have recently made changes to their positions in the business. Kestra Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $27,000. CIBC Private Wealth Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,000. Huntington National Bank lifted its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after purchasing an additional 181 shares during the last quarter. Finally, McIlrath &amp; Eck LLC raised its holdings in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath &amp; Eck LLC now owns 959 shares of the company's stock valued at $75,000 after acquiring an additional 154 shares during the period. 99.95% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近對該公司的持倉進行了調整。Kestra Investment Management LLC 在第四季度購買了 Prestige Consumer Healthcare 的新股份，價值約 27,000 美元。CIBC 私人財富集團在第四季度將其在 Prestige Consumer Healthcare 的股份增加了 48.9%。CIBC 私人財富集團目前擁有該公司 463 股股票，價值 34,000 美元，此前在上個季度又購買了 152 股。Headlands Technologies LLC 在第四季度購買了 Prestige Consumer Healthcare 的新職位，價值約 40,000 美元。亨廷頓國家銀行在第三季度將其在 Prestige Consumer Healthcare 的股份增加了 39.9%。亨廷頓國家銀行目前擁有 635 股該公司的股票，價值 46,000 美元，此前在上個季度又購買了 181 股。最後，McIlrath &amp; Eck LLC 在第四季度將其在 Prestige Consumer Healthcare 的持股增加了 19.1%。McIlrath &amp; Eck LLC 目前擁有該公司 959 股股票，價值 75,000 美元，此前在此期間又收購了 154 股。99.95% 的股票由機構投資者持有。</p>
</div><h2>About Prestige Consumer Healthcare</h2>
<div class="lb-trans"><h2>關於 Prestige Consumer Healthcare</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.</p>
<div class="lb-trans"><p>Prestige Consumer Healthcare Inc 及其子公司在美國和國際上開發、製造、營銷、分銷和銷售非處方（OTC）健康和個人護理產品。該公司分為兩個部門，北美 OTC 醫療保健和國際 OTC 醫療保健。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Prestige Consumer Healthcare</li>
<li>How to Profit From Growth Investing</li>
<li>How to Protect Your Portfolio When Inflation Is Rising</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Prestige Consumer Healthcare</li>
<li>如何從成長投資中獲利</li>
<li>當通貨膨脹上升時，如何保護您的投資組合</li>
<li>精通紀律：克服交易中的情緒挑戰</li>
<li>3 只在 2025 年逆勢而上並蓬勃發展的科技股</li>
<li>想在下跌趨勢中獲利？下跌趨勢解析。</li>
<li>儘管面臨挑戰，Novo Nordisk 計劃擊敗 GLP-1 競爭對手</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元在 Prestige Consumer Healthcare 嗎？</h2>
</div><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Prestige Consumer Healthcare 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Prestige Consumer Healthcare 並不在名單上。</p>
</div><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Prestige Consumer Healthcare 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票的詳情</p>
</div>

StockNews.com 將普雷斯蒂奇消費者健康公司（NYSE:PBH）的評級下調至持有